CC
AXSM icon

Checkpoint Capital’s Axsome Therapeutics AXSM Stock Holding History

Checkpoint Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-174,769
Closed -$14.8M – 16
2024
Q4 		$14.8M Sell
174,769
-34,863
-17% -$3.21M 7.53% 4
2024
Q3 		$18.8M Sell
209,632
-81,140
-28% -$7.08M 9.35% 5
2024
Q2 		$23.4M Buy
290,772
+158,335
+120% +$11.7M 14.11% 3
2024
Q1 		$10.6M Sell
132,437
-22,909
-15% -$1.92M 7.06% 5
2023
Q4 		$12.4M Buy
+155,346
New +$10.4M 7.49% 6

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Checkpoint Capital's AXSM Position: Q1 2025 in Review

Checkpoint Capital sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 174,769 shares — an estimated $14.8M sold.

Checkpoint Capital first reported a position in AXSM in Q4 2023 and held it in 5 quarters. The position peaked at $23.4M in Q2 2024. 352 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • Checkpoint Capital reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Checkpoint Capital sold 174,769 Axsome Therapeutics shares in Q1 2025, an estimated $14.8M.
  • Checkpoint Capital first reported a position in Axsome Therapeutics in Q4 2023 and held it in 5 quarters.
  • Checkpoint Capital's Axsome Therapeutics position peaked at $23.4M in Q2 2024.
  • 352 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on Checkpoint Capital's 13F filing for Q1 2025, filed 15 May 2025.